Clinical trials in Nevada

Reading the Clinical Trial Landscape in Nevada

ClinicalTrials.gov lists 900 clinical trials with study locations in Nevada. Of those, 240 are currently recruiting, roughly 27% of the state's indexed portfolio, above the 14% national average by 13 percentage points, which is a rough but useful proxy for how much research activity is presently open to new participants relative to the rest of the country. The largest status group for Nevada is "Completed" with 445 entries, which sets the overall tone of the registry footprint in this geography. These counts are drawn from the public registry maintained by the National Library of Medicine and are reflected here exactly as indexed; they include every study with at least one site recorded in Nevada, regardless of sponsor type.

The phase distribution shown above breaks the same trials down by where they sit along the investigational pathway. For Nevada, Phase 3 accounts for 263 indexed trials and Phase 2 accounts for 265. Phase 2 studies typically evaluate early efficacy and refine dosing, while Phase 3 studies run larger and are usually closer to regulatory submission, so a state with a strong Phase 3 count often reflects established research centers working on late-stage programs, while a heavier Phase 1 and Phase 2 weighting can indicate concentrations of academic medical centers and early-stage investigator networks. Phase markers come directly from the sponsor-reported registry field and are not transformed on this site.

The most frequently indexed condition for Nevada is Prostate Cancer with 18 linked trials, across 15 top condition areas surfaced above. On the sponsor side, Eli Lilly and Company leads with 32 studies tied to Nevada, with 9 additional organizations in the visible top list. Together, these breakdowns give a quick sense of which conditions and organizations drive trial activity in Nevada, but they do not describe treatment availability, local clinic capacity, or the chance of being matched to any specific study. All numbers come from ClinicalTrials.gov and should be used for reference only, verify current status and eligibility directly on ClinicalTrials.gov, and always discuss clinical trial participation with a qualified healthcare provider before making any decision.